Bristol-Myers Squibb (Switzerland)

Institution (Company)

Homepage Wikipedia ROR

Also Known As

Bristol-Myers Squibb (Switzerland)

Publications

257.2K

Citations

174

Authors

494

Concepts

About

Bristol-Myers Squibb (Switzerland) is a company institution in Steinhausen, Switzerland known for medicine, oncology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Health Sciences	32	121	11.3K
2	Engineering	21	59	3.8K
3	Business	3	5	146
4	Arts	2	2	121
5	Education	2	2	43

Bristol-Myers Squibb (Switzerland)

Publications

257.2K

Citations

Page 1

	Year	Citations
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma Noopur Raje, Jesús G. Berdeja, Yi Lin, New England Journal of Medicine	2019	1.7K
Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive and Triple-Negative Primary Breast Cancers Carsten Denkert, Gϋnter von Minckwitz, Jan C. Brase, Journal of Clinical Oncology	2014	1K
NCCN Guidelines Insights: Colon Cancer, Version 2.2018 Al B. Benson, Alan P. Venook, Mahmoud M. Al-Hawary, Journal of the National Comprehensive Cancer Network	2018	999
Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma Robert Chen, Pier Luigi Zinzani, Michelle A. Fanale, Journal of Clinical Oncology Surgical OncologyImmunologyPathologyPhase Ii StudyPembrolizumab 200	2017	967
Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide Antonia Lopez‐Girona, Derek Mendy, Takumi Ito, Leukemia	2012	783
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial Manali Kamdar, Scott R. Solomon, Jon Arnason, The Lancet Second-line TreatmentSalvage ChemotherapyInterim AnalysisLymphoid NeoplasiaTransplantation	2022	704
PANTHER: a browsable database of gene products organized by biological function, using curated protein family and subfamily classification Paul D. Thomas Nucleic Acids Research	2003	672
Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy Bertrand Coiffier, Barbara Pro, H. Miles Prince, Journal of Clinical Oncology	2012	664
Differential Cytokine Modulation and T Cell Activation by Two Distinct Classes of Thalidomide Analogues That Are Potent Inhibitors of TNF-α Laura G. Corral, Patrick Haslett, George W. Muller, The Journal of Immunology ImmunologyImmune RegulationImmunologic MechanismPharmacotherapyImmunotherapeutics	1999	652
Immunomodulatory agents lenalidomide and pomalidomide co‐stimulate <scp>T</scp> cells by inducing degradation of <scp>T</scp> cell repressors <scp>I</scp> karos and <scp>A</scp> iolos via modulation of the <scp>E</scp> 3 ubiquitin ligase complex <scp>CRL</scp> 4 <scp> <sup>CRBN</sup> </scp> Anita K. Gandhi, Jian Kang, Courtney G. Havens, British Journal of Haematology	2013	611

Page 1